anti-SARS-CoV-2 hyperimmune globulin therapy (Intas)

N/A

Report date: 2025/01/26 19:31:52

Base Information

Drug Nameanti-SARS-CoV-2 hyperimmune globulin therapy (Intas)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntas Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIntas Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A